Patrick Trojer

7.9k total citations · 4 hit papers
58 papers, 5.3k citations indexed

About

Patrick Trojer is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Patrick Trojer has authored 58 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 10 papers in Hematology and 7 papers in Oncology. Recurrent topics in Patrick Trojer's work include Epigenetics and DNA Methylation (36 papers), Cancer-related gene regulation (25 papers) and Genomics and Chromatin Dynamics (15 papers). Patrick Trojer is often cited by papers focused on Epigenetics and DNA Methylation (36 papers), Cancer-related gene regulation (25 papers) and Genomics and Chromatin Dynamics (15 papers). Patrick Trojer collaborates with scholars based in United States, Austria and United Kingdom. Patrick Trojer's co-authors include Danny Reinberg, Raphaël Margueron, Guohong Li, John P. McGrath, Bing Zhu, Subhrangsu S. Mandal, Rushad Pavri, Ali Shilatifard, Raffaella Villa and Kai-Ping Yan and has published in prestigious journals such as Science, Cell and Nucleic Acids Research.

In The Last Decade

Patrick Trojer

58 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination

2007 599 citations Patrick Trojer, Danny Reinberg et al. profile →
Histone H2B Monoubiquitination Functions Cooperatively with FACT to Regulate Elongation by RNA Polymerase II

2006 576 citations Rushad Pavri, Bing Zhu et al. Cell profile →
The key to development: interpreting the histone code?

2005 574 citations Raphaël Margueron, Patrick Trojer et al. profile →
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy

2018 182 citations Sangeeta Goswami, Irina Apostolou et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Trojer United States	33	4.7k	483	454	378	318	58	5.3k
Christian A. Hassig United States	19	5.2k 1.1×	919 1.9×	977 2.2×	268 0.7×	298 0.9×	40	5.9k
Alexander J. Ruthenburg United States	23	4.9k 1.0×	375 0.8×	329 0.7×	335 0.9×	340 1.1×	36	5.3k
Scott Briggs United States	32	6.1k 1.3×	489 1.0×	456 1.0×	875 2.3×	224 0.7×	50	6.9k
Xiang-Jiao Yang Canada	24	3.8k 0.8×	710 1.5×	621 1.4×	202 0.5×	244 0.8×	32	4.2k
Michael J. Pazin United States	25	4.0k 0.8×	530 1.1×	441 1.0×	402 1.1×	393 1.2×	35	4.7k
Haijuan Yang United States	13	4.5k 1.0×	674 1.4×	692 1.5×	221 0.6×	444 1.4×	20	5.1k
Ian G. Cowell United Kingdom	29	2.7k 0.6×	297 0.6×	778 1.7×	300 0.8×	265 0.8×	65	3.2k
Kenichi Nishioka Japan	22	4.0k 0.8×	600 1.2×	283 0.6×	329 0.9×	327 1.0×	43	4.7k
Robert J. Sims United States	27	5.6k 1.2×	438 0.9×	736 1.6×	325 0.9×	351 1.1×	50	6.1k
Zhanyun Tang United States	28	4.3k 0.9×	291 0.6×	612 1.3×	531 1.4×	320 1.0×	33	4.9k

Countries citing papers authored by Patrick Trojer

Since Specialization

Citations

This map shows the geographic impact of Patrick Trojer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Trojer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Trojer more than expected).

Fields of papers citing papers by Patrick Trojer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Trojer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Trojer. The network helps show where Patrick Trojer may publish in the future.

Co-authorship network of co-authors of Patrick Trojer

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Trojer. A scholar is included among the top collaborators of Patrick Trojer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Trojer. Patrick Trojer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Supko, Jeffrey G., Michael B. Maris, Ian W. Flinn, et al.. (2022). A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer Research Communications. 2(8). 795–805. 23 indexed citations

Stuckey, Jacob I., Nico Cantone, Alexandre Côté, et al.. (2021). Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity. Journal of Biological Chemistry. 296. 100349–100349. 9 indexed citations

Park, Donglim Esther, Jingwei Cheng, John P. McGrath, et al.. (2020). Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis. Nature Cell Biology. 22(5). 603–615. 49 indexed citations

Mascarenhas, John, Marina Kremyanskaya, Ronald Hoffman, et al.. (2019). MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood. 134(Supplement_1). 670–670. 36 indexed citations

Harb, Wael A., Jeremy S. Abramson, Matthew A. Lunning, et al.. (2018). A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. Annals of Oncology. 29. iii7–iii7. 24 indexed citations

Goswami, Sangeeta, Irina Apostolou, Jan Zhang, et al.. (2018). Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy. Journal of Clinical Investigation. 128(9). 3813–3818. 182 indexed citations breakdown →

Leadem, Benjamin R., Ioannis Kagiampakis, Catherine Wilson, et al.. (2017). A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2′-Deoxycytidine. Cancer Research. 78(5). 1127–1139. 37 indexed citations

McGrath, John P., Kaylyn E. Williamson, Srividya Balasubramanian, et al.. (2016). Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. Cancer Research. 76(7). 1975–1988. 70 indexed citations

Egan, Brian, Chih-Chi Yuan, Madeleine Craske, et al.. (2016). An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition. PLoS ONE. 11(11). e0166438–e0166438. 85 indexed citations

10.

Maile, Tobias M, Anita Izrael-Tomasevic, Tommy K. Cheung, et al.. (2015). Mass Spectrometric Quantification of Histone Post-translational Modifications by a Hybrid Chemical Labeling Method. Molecular & Cellular Proteomics. 14(4). 1148–1158. 77 indexed citations

11.

McGrath, John P. & Patrick Trojer. (2015). Targeting histone lysine methylation in cancer. Pharmacology & Therapeutics. 150. 1–22. 150 indexed citations

12.

Nasveschuk, Christopher G., Alexandre Gagnon, Eric Y. Chan, et al.. (2013). Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth. Chemistry & Biology. 20(11). 1329–1339. 116 indexed citations

13.

Trojer, Patrick, Zhonghua Gao, Yan Li, et al.. (2011). L3MBTL2 Protein Acts in Concert with PcG Protein-Mediated Monoubiquitination of H2A to Establish a Repressive Chromatin Structure. Molecular Cell. 42(4). 438–450. 113 indexed citations

14.

Beck, David B., Roberto Bonasio, Syuzo Kaneko, et al.. (2010). Chromatin in the Nuclear Landscape. Cold Spring Harbor Symposia on Quantitative Biology. 75(0). 11–22. 21 indexed citations

15.

Li, Yan, Patrick Trojer, Chong‐Feng Xu, et al.. (2009). The Target of the NSD Family of Histone Lysine Methyltransferases Depends on the Nature of the Substrate. Journal of Biological Chemistry. 284(49). 34283–34295. 237 indexed citations

16.

Xu, Chong‐Feng, et al.. (2009). Identification and Characterization of a Novel Nuclear Protein Complex Involved in Nuclear Hormone Receptor-mediated Gene Regulation. Journal of Biological Chemistry. 284(12). 7542–7552. 67 indexed citations

17.

Trojer, Patrick, Guohong Li, Robert J. Sims, et al.. (2007). L3MBTL1, a Histone-Methylation-Dependent Chromatin Lock. Cell. 129(5). 915–928. 267 indexed citations

18.

Pavri, Rushad, Bing Zhu, Guohong Li, et al.. (2006). Histone H2B Monoubiquitination Functions Cooperatively with FACT to Regulate Elongation by RNA Polymerase II. Cell. 125(4). 703–717. 576 indexed citations breakdown →

19.

Trojer, Patrick & Danny Reinberg. (2006). Histone Lysine Demethylases and Their Impact on Epigenetics. Cell. 125(2). 213–217. 174 indexed citations

20.

Trojer, Patrick, Petra Wojnar, Petra Merschak, & Bernhard Redl. (1999). Complement component C8γ is expressed in human fetal and adult kidney independent of C8α. FEBS Letters. 446(2-3). 243–246. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact